Tumor Burden and Intraosseous Metabolic Activity as Predictors of Bone Marrow Failure during Radioisotope Therapy in Metastasized Prostate Cancer Patients.

about

Tumor Burden and Intraosseous Metabolic Activity as Predictors of Bone Marrow Failure during Radioisotope Therapy in Metastasized Prostate Cancer Patients.

Item

http://www.wikidata.org/entity/Q49732567

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Tumor Burden and Intraosseous ...... ized Prostate Cancer Patients.

@en

Tumor Burden and Intraosseous ...... ized Prostate Cancer Patients.

@nl

type

Item

label

Tumor Burden and Intraosseous ...... ized Prostate Cancer Patients.

@en

Tumor Burden and Intraosseous ...... ized Prostate Cancer Patients.

@nl

prefLabel

Tumor Burden and Intraosseous ...... ized Prostate Cancer Patients.

@en

Tumor Burden and Intraosseous ...... ized Prostate Cancer Patients.

@nl

P1476

Tumor Burden and Intraosseous ...... ized Prostate Cancer Patients.

@en

P2093

Christian la Fougère

http://www.w3.org/2001/XMLSchema#string

Helmut Dittmann

http://www.w3.org/2001/XMLSchema#string

Matthias Weissinger

http://www.w3.org/2001/XMLSchema#string

Michele Piana

http://www.w3.org/2001/XMLSchema#string

Samine Sahbai

http://www.w3.org/2001/XMLSchema#string

P2860

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials.

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 A

Clinical Efficacy and Safety Comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases.

Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone.

Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.

One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.

A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy.

Improving the interpretation of bone marrow imaging in cancer patients.

P304

3905216

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2017/3905216

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-12-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29435457

http://www.w3.org/2001/XMLSchema#string

P932

5757096

http://www.w3.org/2001/XMLSchema#string